3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Moderate Hepatic Impairment
1
Meningioma
1
Healthy Participants
1
Glioma
1
Esophageal Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinosarcoma
1
Interventions
Fulvestrant
4
ribociclib
2
palbociclib
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tivozanib
1
serabelisib
1
sapanisertib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
cemiplimab
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
STX-478
1
Paclitaxel
1
Metformin
1
Lomustine
1
Letrozole
1
Imlunestrant
1
Doxorubicin
1
Cetuximab
1
Carboplatin
1
CA-4948
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
capivasertib
×
90 days
×
Clear all
No trials found.